Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida
Tryp Therapeutics (TRYP) began enrolling patients for a Phase 2 trial on psilocybin for binge eating. The company is using non-proprietary synthetic psilocybin to generate data quickly while developing a proprietary formulation.